StreetInsider.com News Articles

Medpace (MEDP) PT Raised to $565 at Baird

Mon, 09 Mar 2026 06:19:23 -0400

Baird analyst Eric Coldwell raised the price target on Medpace (NASDAQ: MEDP) to $565.00 (from $564.00) while maintaining a Outperform rating.

Barclays Upgrades Medpace (MEDP) to Equalweight

Fri, 06 Mar 2026 06:18:56 -0400

(Updated - March 6, 2026 6:18 AM EST)

Barclays analyst Luke Sergott upgraded Medpace (NASDAQ: MEDP) from Underweight to Equalweight with a price target of $500.00.

The analyst comments "We upgrade MEDP to Equal Weight and maintain our $500 price target. The crux of our previous Underweight rating centered mostly around valuation and the premium being granted to the business and how this did not account for the potential air gap and growth deceleration coming from faster burning business rolling off faster than traditional work ramping. MEDP deserves a premium, in our view, and it has meaningfully closed the gap vs. peers

Barclays Upgrades Medpace (MEDP) to Equalweight

Fri, 06 Mar 2026 06:18:56 -0400

(Updated - March 6, 2026 6:18 AM EST)

Barclays analyst Luke Sergott upgraded Medpace (NASDAQ: MEDP) from Underweight to Equalweight with a price target of $500.00.

RBC Capital Starts Medpace (MEDP) at Outperform

Tue, 03 Mar 2026 02:18:48 -0400

RBC Capital analyst Ryan Halsted initiates coverage on Medpace (NASDAQ: MEDP) with a Outperform rating and a price target of $522.00.

The analyst comments: "We are initiating coverage of Medpace with an Outperform rating and a $522 price target. Medpace is the most efficient CRO per employee and most significantly levered to the biopharma end markets where we are seeing the strongest green shoots in terms of clinical trial activity and thus CRO activity in early 2026, further supporting their segment-leading growth and margins ahead of their larger peers. Our proprietary analysis into trial cancellations appear to be endpoint-data driven and

RBC Capital Starts Medpace (MEDP) at Outperform

Tue, 03 Mar 2026 02:18:48 -0400

RBC Capital analyst Ryan Halsted initiates coverage on Medpace (NASDAQ: MEDP) with a Outperform rating and a price target of $522.00.

Form 4 Medpace Holdings, Inc. For: Feb 17 Filed by: EWALD STEPHEN P

Wed, 18 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260218/26023224.html

Form 4 Medpace Holdings, Inc. For: Feb 17 Filed by: EWALD STEPHEN P

Wed, 18 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260218/26023224.html

TD Cowen Upgrades Medpace (MEDP) to Hold

Wed, 18 Feb 2026 07:12:16 -0400

(Updated - February 18, 2026 7:12 AM EST)

TD Cowen analyst Charles Rhyee upgraded Medpace (NASDAQ: MEDP) from Sell to Hold with a price target of $419.00 (from $462.00).

The analyst commented: "We upgrade MEDP to Hold from Sell. With MEDP having re-rated from a peak multiple, we believe shr price now reflects fair value. We also think 2026 B2Bs should benefit from improving biotech macro. While we think MEDP's focus on biotech should help it retain more AI-driven savings vs peers, uncertainty on AI impact could be an overhang. Our $419 price target implies shrs can trade at 25x 2026 EPS."

For

TD Cowen Upgrades Medpace (MEDP) to Hold

Wed, 18 Feb 2026 07:12:16 -0400

(Updated - February 18, 2026 7:12 AM EST)

TD Cowen analyst Charles Rhyee upgraded Medpace (NASDAQ: MEDP) from Sell to Hold with a price target of $419.00 (from $462.00).

For

TD Cowen Upgrades Medpace (MEDP) to Hold

Wed, 18 Feb 2026 07:12:16 -0400

(Updated - February 18, 2026 7:12 AM EST)

TD Cowen analyst Charles Rhyee upgraded Medpace (NASDAQ: MEDP) from Sell to Hold with a price target of $419.00 (from $462.00).

For

Form 4 Medpace Holdings, Inc. For: Feb 13 Filed by: Carley Brian T

Tue, 17 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260217/26014771.html

Form 4 Medpace Holdings, Inc. For: Feb 13 Filed by: Carley Brian T

Tue, 17 Feb 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260217/26014771.html

Form 4 Medpace Holdings, Inc. For: Feb 13 Filed by: BURWIG SUSAN E

Tue, 17 Feb 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260217/26014322.html

Form 4 Medpace Holdings, Inc. For: Feb 13 Filed by: BURWIG SUSAN E

Tue, 17 Feb 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260217/26014322.html

Jefferies Upgrades Medpace (MEDP) to Buy

Fri, 13 Feb 2026 01:08:49 -0400

Jefferies analyst David Windley upgraded Medpace (NASDAQ: MEDP) from Hold to Buy with a price target of $560.00.

The analyst comments: "Biotech funding has inflected meaningfully in 2H25, with a durable backdrop and a well‑established 12-15-month lag setting up bookings acceleration through 2H26. With AI posing less near‑term risk to full‑service CROs, valuation reset to trough levels, and guidance conservatively assuming elevated cancellations, risk/reward is skewed favorably ahead of a potential demand and earnings inflection. Upgrade MEDP to Buy."

For an analyst ratings summary and ratings history on Medpace click here. For more ratings news on Medpace click here.

Shares of

Jefferies Upgrades Medpace (MEDP) to Buy

Fri, 13 Feb 2026 01:08:49 -0400

Jefferies analyst David Windley upgraded Medpace (NASDAQ: MEDP) from Hold to Buy with a price target of $560.00.

For an analyst ratings summary and ratings history on Medpace click here. For more ratings news on Medpace click here.

Shares of

Medpace (MEDP) PT Lowered to $460 at BMO Capital

Wed, 11 Feb 2026 08:53:32 -0400

BMO Capital analyst Sean Dodge lowered the price target on Medpace (NASDAQ: MEDP) to $460.00 (from $600.00) while maintaining a Market Perform rating.

The analyst commented: "Cancellations, Broader Negative AI Sentiment Overshadow Otherwise Strong Results; MEDP's premium valuation meant expectations regarding execution were high heading into the 4Q print, and while the company delivered better-than-expected 4Q results and debuted '26 EBITDA/EPS guidance slightly ahead of Street (revenue ~inline), a surprise uptick in 4Q metabolic cancellations (which has been one of the primary recent growth drivers) combined with the ongoing perception of broader AI CRO disintermediation, is further weighing on shares. We

Medpace (MEDP) PT Lowered to $460 at BMO Capital

Wed, 11 Feb 2026 08:53:32 -0400

BMO Capital analyst Sean Dodge lowered the price target on Medpace (NASDAQ: MEDP) to $460.00 (from $600.00) while maintaining a Market Perform rating.

Medpace (MEDP) PT Lowered to $539 at Truist Securities

Wed, 11 Feb 2026 07:06:11 -0400

Truist Securities analyst Jailendra Singh lowered the price target on Medpace (NASDAQ: MEDP) to $539.00 (from $555.00) while maintaining a Hold rating.

Medpace (MEDP) PT Lowered to $582 at Mizuho

Wed, 11 Feb 2026 06:51:45 -0400

Mizuho analyst Ann Hynes lowered the price target on Medpace (NASDAQ: MEDP) to $582.00 (from $660.00) while maintaining a Outperform rating.

Baird Upgrades Medpace (MEDP) to Outperform

Wed, 11 Feb 2026 05:20:52 -0400

Baird analyst Eric Coldwell upgraded Medpace (NASDAQ: MEDP) from Neutral to Outperform with a price target of $564.00.

The analyst comments "Pardon the interruption. We don’t typically change ratings midday, but this is a rare event. It wasn’t a perfect update nor is the sector easy in the moment. However, we think the Street doesn’t get the whole story on AI and we’ve long bemoaned failing to pull the trigger on MEDP when the market gave us a more palatable entry."

For an analyst ratings summary and ratings history on Medpace click here. For more ratings news on Medpace click

Baird Upgrades Medpace (MEDP) to Outperform

Wed, 11 Feb 2026 05:20:52 -0400

Baird analyst Eric Coldwell upgraded Medpace (NASDAQ: MEDP) from Neutral to Outperform with a price target of $564.00.

For an analyst ratings summary and ratings history on Medpace click here. For more ratings news on Medpace click

Medpace (MEDP) PT Lowered to $485 at Leerink Partners

Tue, 10 Feb 2026 16:09:47 -0400

Leerink Partners analyst Michael Cherny lowered the price target on Medpace (NASDAQ: MEDP) to $485.00 (from $575.00) while maintaining a Market Perform rating.

The analyst comments "MEDP's broader business prospects appear fine, but a less-clean 4Q did leave us with more questions than answers for 2026. Quarterly cancellations were higher than anticipated, with backlog cancellations at particularly elevated rates. This was a surprise with broader CRO KPIs pointing in the right direction and off an improvement in cancellations in 3Q. Commentary suggests that the business environment is unchanged, and that cancels (more prevalent in cardiometabolic trials) were unexpected. Although the broader

Medpace (MEDP) PT Lowered to $485 at Leerink Partners

Tue, 10 Feb 2026 16:09:47 -0400

Leerink Partners analyst Michael Cherny lowered the price target on Medpace (NASDAQ: MEDP) to $485.00 (from $575.00) while maintaining a Market Perform rating.

Form 10-K Medpace Holdings, Inc. For: Dec 31

Tue, 10 Feb 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260210/25975429.html